Back to Directory

SynaptixBio

Antisense oligonucleotide therapies for TUBB4A-associated leukodystrophies

SynaptixBio is a biotechnology company developing antisense oligonucleotide therapies for severe inherited leukodystrophies.

Its lead programme targets TUBB4A-associated hypomyelinating disorders, including hypomyelination with atrophy of the basal ganglia and cerebellum (H-ABC). The approach uses synthetic oligonucleotides to suppress disease-associated TUBB4A expression.

The company has selected a development candidate and holds US orphan drug designations for relevant TUBB4A disorders. Its lead therapy remains in development ahead of clinical testing.